MR45625 - Ranibizumab with Port Delivery System in nAMD - Sightspire
Research type
Research Study
Full title
A PHASE IIIb, MULTICENTER, SINGLE-ARM STUDY ASSESSING THE EFFECTIVENESS, SAFETY AND PATIENT REPORTED OUTCOMES OF A 36-WEEK REFILL EXCHANGE REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - SIGHTSPIRE
IRAS ID
1011768
Contact name
Shady Mansour
Contact email
Sponsor organisation
F. Hoffmann- La Roche AG
Clinicaltrials.gov Identifier
Research summary
Neovascular age-related macular degeneration, also called wet age-related macular degeneration(AMD)is a form of advanced AMD that causes rapid&severe visual loss&remains a leading cause of visual impairment in older adults.
Current treatment options include anti-vascular endothelial growth factor(VEGF) intravitreal(IVT) injections, which have been shown to stabilize&prevent vision loss in the majority of patients. However, a significant challenge with anti-VEGF therapy is the need for frequent&long-term administration due to the chronic nature of nAMD. Frequent IVT injections can place a substantial burden on individuals with nAMD, their caregivers,& the healthcare system. Therefore, there is a need for treatments that require less frequent dosing while still providing robust visual acuity(VA)benefits.
The PDS implant is an intraocular refillable device that is surgically implanted through the pars plana to allow for a continuous delivery of ranibizumab into the vitreous. It is used in conjunction with a customized formulation of 100 mg/mL ranibizumab to precisely control the rate & duration of drug delivery & is refillable through the implant septum in situ.The PDS has been developed to address this unmet medical need by reducing the overall visit & treatment burden while achieving & maintaining optimal visual outcomes. The PDS with refills performed every 24 weeks has been approved in the United States for the treatment of nAMD since October 2021.
The purpose of this study is to assess the effectiveness,safety&patient-reported outcomes(PROs) of the Port Delivery System with ranibizumab(PDS)with a 36-week refill cycle(Q36W)in patients with nAMD.
Globally,250 Participants with nAMD will be recruited with 19 from the UK across 6 sites
The study will last approximately 19 months for each participant however participants may continue to receive treatment until HA approval.
The study is sponsored by F.Hoffmann- La Roche
Research Summary; Version 1 19-May-2025REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
25/WM/0164
Date of REC Opinion
2 Oct 2025
REC opinion
Further Information Favourable Opinion